Tag: FDA
FASTER Act Requires Sesame to be Included as Allergen on Food Labels
Washington, D.C.—On April 14, the U.S. Congress passed the Food Allergy Safety, Treatment, Education, and Research (FASTER) Act of 2021; on April 23, President...
DSQC Calls Industry to Action on 3 Fronts
“Big picture: The important thing here is that the supplement industry has grown tremendously over the last 20+ years,” said DSQC Steering Committee Chair...
Is Your Immune-Health Structure/Function Claim Making Implied COVID-19 Disease Claims?
Mitigate the Regulatory Risk by Prioritizing Claim Substantiation
Three current trends in consumer retail behavior reflect the changes in consumer attitudes caused by coronavirus disease...
FDA Warns 2 Companies for Misbranding Pain Relief Products Containing CBD
Silver Spring, MD—FDA has issued warning letters to two companies for selling products labeled as containing cannabidiol (CBD) in ways that violate the FD&C...
Federal Judge Enters Permanent Injunction Against NY-Based Supplement Manufacturer
Silver Spring, MD—The Food and Drug Administration (FDA) issued a news release announcing that Judge Edward R. Korman, of the U.S. District Court for...
CRN Requests Confirmation that FDA Proposed Traceability Rule Won’t Affect Supplements
Washington, D.C.—The Council for Responsible Nutrition has submitted comments on FDA’s Proposed Rule for Requirements for Additional Traceability Records for Certain Foods, asking for...
FDA Warns Companies for Mental Health Claims
Silver Spring, MD—FDA has warned 10 companies for illegally selling supplements claiming to treat mental health disorders, according to a press release.
The warning letters...
Industry Reacts to FDA’s ODSP Leadership Change
Washington, D.C.—Effective March 15, 2021, Steve Tave will transition from his role as Director of FDA's Office of Dietary Supplements Programs (ODSP) to a...
“Critical” Bill to Legalize Hemp, CBD Introduced in Congress
Washington, D.C.—Representatives Kurt Schrader (D-OR) and Morgan Griffith (R-VA) have introduced a bill that would allow hemp and cannabidiol (CBD) to be marketed and...
CRN “Disappointed” with FDA Withdrawal of “Cannabidiol Enforcement Policy; Draft Guidance for Industry”
Following a Biden administration memo to all federal agencies directing them to withdraw pending rules, the Federal Drug Administration (FDA) has withdrawn its "Cannabidiol...
